Cargando…

Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women

Most human immunodeficiency virus (HIV) infections occur in cisgender women in resource-limited settings. In women, self-protection with emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis (FTC/TDF-PrEP) constitutes a major pillar of HIV prevention. However, clinical trials in women...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lanxin, Iannuzzi, Sara, Chaturvedula, Ayyappa, Irungu, Elizabeth, Haberer, Jessica E., Hendrix, Craig W., von Kleist, Max
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667095/ https://www.ncbi.nlm.nih.gov/pubmed/37957377 http://dx.doi.org/10.1038/s41591-023-02615-x

Ejemplares similares

Synthesis of protective oral PrEP adherence levels in cisgender women using convergent clinical- and bottom-up modeling
por: Zhang, Lanxin, et al.
Publicado: (2023)

Assessment of Demographic and Socio-Behavioral Factors on Adherence to HIV Pre-Exposure Prophylaxis Using a Markov Modeling Approach
por: Mallayasamy, Surulivelrajan, et al.
Publicado: (2019)

Editorial: Pharmacokinetics and Pharmacodynamics of Pre-Exposure Prophylaxis Against HIV
por: von Kleist, Max, et al.
Publicado: (2020)

Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study
por: Roberts, Sarah T., et al.
Publicado: (2016)

Transgender women on oral HIV pre‐exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men
por: Shieh, Eugenie, et al.
Publicado: (2019)

Population pharmacokinetics of tenofovir and tenofovir‐diphosphate in healthy women
por: Burns, Rebecca N., et al.
Publicado: (2015)

Understanding Pre-Exposure Prophylaxis Adherence in Young Women in Kenya
por: Haberer, Jessica E., et al.
Publicado: (2022)

Pre-Exposure Prophylaxis (PrEP) for HIV Infection in Cisgender and Transgender Women in the U.S.: A Narrative Review of the Literature
por: Baldwin, Aleta, et al.
Publicado: (2021)

US Black cisgender women and pre-exposure prophylaxis for human immunodeficiency virus prevention: A scoping review
por: Conley, Cherie, et al.
Publicado: (2022)

HIV-1 self-testing to improve the efficiency of pre-exposure prophylaxis delivery: a randomized trial in Kenya
por: Ortblad, Katrina F., et al.
Publicado: (2019)

“PrEP’s just to secure you like insurance”: a qualitative study on HIV pre-exposure prophylaxis (PrEP) adherence and retention among black cisgender women in Mississippi
por: Willie, Tiara C., et al.
Publicado: (2021)

Evaluation of multiple data sources for predicting increased need for HIV prevention among cisgender women: understanding missed opportunities for Pre-exposure Prophylaxis (PrEP)
por: Johnson, Amy K., et al.
Publicado: (2023)

1843. Exploring Cisgender Women's HIV Pre-Exposure Prophylaxis (PrEP) Needs and Preferences Across Settings: the Roles of Social-Structural Factors
por: Kerrigan, Deanna, et al.
Publicado: (2023)

Mathematical Modelling of the Molecular Mechanisms of Interaction of Tenofovir with Emtricitabine against HIV
por: Iannuzzi, Sara, et al.
Publicado: (2021)

Roll-out of HIV pre-exposure prophylaxis: a gateway to mental health promotion
por: Ikeda, Daniel J, et al.
Publicado: (2021)

Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence
por: Haberer, Jessica E., et al.
Publicado: (2017)

Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya
por: Mugo, Peter Mwangi, et al.
Publicado: (2014)

High Medication Adherence During Periconception Periods Among HIV-1–Uninfected Women Participating in a Clinical Trial of Antiretroviral Pre-exposure Prophylaxis
por: Matthews, Lynn T., et al.
Publicado: (2014)

A Systematic Evaluation of Effect of Adherence Patterns on the Sample Size and Power of a Clinical Study
por: Mallayasamy, Surulivelrajan, et al.
Publicado: (2018)

Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting
por: Montgomery, Madeline C., et al.
Publicado: (2016)

Characterizing Awareness of Pre-Exposure Prophylaxis for HIV Prevention in Manila and Cebu, Philippines: Web-Based Survey of Filipino Cisgender Men Who Have Sex With Men
por: Restar, Arjee, et al.
Publicado: (2022)

Performance of self-reported adherence to oral pre-exposure prophylaxis (PrEP) among HIV heterosexual serodiscordant couples in rural Uganda
por: Kibengo, FM, et al.
Publicado: (2012)

Comparing Self-Report Pre-Exposure Prophylaxis Adherence Questions to Pharmacologic Measures of Recent and Cumulative Pre-Exposure Prophylaxis Exposure
por: Blumenthal, Jill, et al.
Publicado: (2019)

Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes
por: Duwal, Sulav, et al.
Publicado: (2018)

Numerical approaches for the rapid analysis of prophylactic efficacy against HIV with arbitrary drug-dosing schemes
por: Zhang, Lanxin, et al.
Publicado: (2021)

Feasibility and acceptability of HIV self-testing among pre-exposure prophylaxis users in Kenya
por: Ngure, Kenneth, et al.
Publicado: (2017)

Safety and Adherence to Intermittent Pre-Exposure Prophylaxis (PrEP) for HIV-1 in African Men Who Have Sex with Men and Female Sex Workers
por: Mutua, Gaudensia, et al.
Publicado: (2012)

Impact of daily, oral pre-exposure prophylaxis on the risk of bacterial sexually transmitted infections among cisgender women: a systematic review and narrative synthesis
por: Papageorgiou, Vasiliki, et al.
Publicado: (2022)

Pre-exposure prophylaxis of HIV
por: Naswa, Smriti, et al.
Publicado: (2011)

Pre-exposure prophylaxis in HIV
por: Khambhati, Ravi, et al.
Publicado: (2009)

HIV: Pre-exposure Prophylaxis
por: Singh, Ajai Kumar, et al.
Publicado: (2012)

Comparison of adherence measurement tools used in a pre-exposure prophylaxis demonstration study among female sex workers in Benin
por: Mboup, Aminata, et al.
Publicado: (2020)

Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis
por: Duwal, Sulav, et al.
Publicado: (2019)

Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy
por: Scott, Rachel K., et al.
Publicado: (2023)

A Scoping Review of Oral Pre-exposure Prophylaxis for Cisgender and Transgender Adolescent Girls and Young Women: What Works and Where Do We Go from Here?
por: Dayton, Robyn L., et al.
Publicado: (2023)

HIV pre-exposure prophylaxis for women
por: Sheth, Anandi N, et al.
Publicado: (2016)

Modeling HIV Pre-Exposure Prophylaxis
por: Straubinger, Thomas, et al.
Publicado: (2020)

Prescribing pre-exposure prophylaxis for HIV
por: Bloch, Mark
Publicado: (2020)

Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1–Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda
por: Baeten, Jared M., et al.
Publicado: (2016)

Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women
por: Tanaudommongkon, Asama, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jaqhndsgmm1cb8dv7dabpj5de1